Adagene Inc. Stock News

- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-

Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.

Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.

– Adagene's CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies –

Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so far this year.

SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today anno

SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today

The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrol

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Associatio

- New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company’s AI-powered platform -

Check out the story - Adagene, Sanofi signs collaboration and license deal worth up to $2.5bn on Business-News-Today.com posted under Pharma Industry News.

Sanofi SA (NASDAQ: SNY ) has signed a collaboration with Adagene Inc (NASDAQ: ADAG ) to advance two preclinical immuno-oncology candidates and an option to develop two more. Sanofi is paying $17.5 million upfront and promising up to $2.5 billion in potential milestones. Under the terms of the agreement, … Full story available on Benzinga.com

Shares of Adagene Inc. jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi that is worth up to $2.5 billion. U.S.-listed shares of Sanofi were down 1.5%. Adagene will develop masked versions of up to four of Sanofi''s antibodies in development. Per the terms of the deal, Sanofi will pay Adadene $17.5 million now; however, the milestone payments are worth up to $2.5 billion, and the company is eligible for royalties based on sales of the therapies if they are commercialized. Adagene''s stock has tumbled 77.6% over the past year, while the S&P 500 is up 10.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.